Skip to main content
SpringerLink
Log in

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

  • Original paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The human multidrug resistance gene (MDR1, ABCB1) codes for P-glycoprotein (P-gp) that affects the pharmacokinetics of many drugs. MDR1 single nucleotide polymorphisms (SNPs) are associated with drug clearance. Imatinib is a substrate of P-gp-mediated efflux. We investigated the MDR1 T1236C, G 2677T/A, and C3435T polymorphism in 52 patients with chronic myeloid leukemia treated with imatinib. The distribution of MDR1 1236, 2677, or 3435 genotypes was significantly different between the resistance patients and sensitivity patients. The resistance incidence correlated with the number of T alleles at locus 1236 and 3435. Resistance was higher for patients homozygous for the 1236T allele when compared to patients with CT/CC genotype groups (75% vs. 31.3%, P = 0.004). For the G2677T/A polymorphism, a better complete cytogenetic remission was observed for patients with genotype AG/AT/AA, when compared to other genotype groups (TT/GT/GG, P = 0.02). Patients with 3435 TT/CT genotypes showed a higher resistance when compared with patients with CC genotype (59.4% vs. 25%, P = 0.023). In conclusion, determination of 1236T, C3435T, and G2677T MDR1 polymorphisms might be useful in response prediction to therapy with imatinib in patients with CML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–41.

    Article  PubMed  CAS  Google Scholar 

  2. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112(5):2024–7.

    Article  PubMed  CAS  Google Scholar 

  3. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525–8.

    Article  PubMed  CAS  Google Scholar 

  4. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–8.

    Article  PubMed  CAS  Google Scholar 

  5. Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007;82(1):33–40.

    Article  PubMed  CAS  Google Scholar 

  6. Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics. 2007;8(1):29–39.

    Article  PubMed  CAS  Google Scholar 

  7. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72(5):314–21.

    Article  PubMed  CAS  Google Scholar 

  8. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, et al. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005;528(1–3):27–36.

    Article  PubMed  CAS  Google Scholar 

  9. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National natural science foundation of P.R. China (Project No. 30700461).

Conflict of interest

We do not have any conflicts of interest regarding our manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital, Nanjing Medical University, 300 Guangzhou Rd, 210029, Nanjing, China

    Ling-Na Ni, Jian-Yong Li, Kou-Rong Miao, Chun Qiao, Su-Jiang Zhang, Hai-Rong Qiu & Si-Xuan Qian

Authors
  1. Ling-Na Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kou-Rong Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Su-Jiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hai-Rong Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Si-Xuan Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Si-Xuan Qian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ni, LN., Li, JY., Miao, KR. et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28, 265–269 (2011). https://doi.org/10.1007/s12032-010-9456-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9456-9

Keywords

Search

Navigation